What is the scoring method for HER2 expression in breast cancer testing?

1. Moasser MM, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncol. 2015 Jul 23. [Medline].

2. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013 Oct 7. [Medline].

3. Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, et al. Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol. 2015 Feb. 68 (2):93-9. [Medline].

4. Penault-Llorca F, Vincent-Salomon A, Mathieu MC, et al. [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. Ann Pathol. 2014 Oct. 34 (5):352-65. [Medline].

5. Bianchi S, Caini S, Paglierani M, Saieva C, Vezzosi V, Baroni G, et al. Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations. Pathol Oncol Res. 2015 Apr. 21 (2):477-85. [Medline].

6. Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy (HERCREEM). ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT00889954. September 18, 2018; Accessed: May 14, 2019.

7. [Guideline] Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. Jan 1 2007. 25(1):118-45.

8. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6. 365(14):1273-83. [Medline].

9. Herceptin Hylecta (trastuzumab/hyaluronidase) [package insert]. South San Francisco, CA: Genentech, Inc. February, 2019. Available at [Full Text].

10. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012 Sep. 13 (9):869-78. [Medline]. [Full Text].

11. Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, et al. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. Eur J Cancer. 2017 Sep. 82:237-246. [Medline]. [Full Text].

12. von Minckwitz G, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14. 380 (7):617-628. [Medline].

13. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008 Dec 1. 26(34):5544-52. [Medline]. [Full Text].

14. neratinib (Nerlynx) [package insert]. 10880 Wilshire Blvd., Suite 2150 Los Angeles, CA 90024-4106: Puma Biotechnology, Inc. 7/2017. Available at [Full Text].

15. Chan A, Delaloge S, Holmes FA. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar. 17 (3):367-77. [Medline]. [Full Text].

16. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12. 366(2):109-19. [Medline].

17. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan. 13(1):25-32. [Medline].

18. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8. 367(19):1783-91. [Medline].

19. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15. 344(11):783-92. [Medline]. [Full Text].

20. Von Minckwitz G, Zielinski C, Maarteense E, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05) Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008:1025.

21. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008 Jun. 83(6):679-86. [Medline].

22. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 1. 28(7):1124-30. [Medline].

23. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012 Oct 1. [Medline].

24. Modi S, Saura C, Yamashita T, and the, DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019 Dec 11. [Medline].

25. Enhertu (trastuzumab deruxtecan) [package insert]. Wilmington, DE: Daiichi Sankyo Company, Ltd. December 2019. Available at [Full Text].

26. Murthy RK, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 Feb 13. 382 (7):597-609. [Medline].

27. Vukelja S, Rugo H, Vogel C, et al. A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. Cancer Res. 2009. 69(suppl 2):71s:Abstract 33.

28. Ogivri (trastuzumab-dkst) [package insert]. Zurich, Switzerland: Mylan GmbH. December 2018. Available at [Full Text].

29. Herzuma (trastuzumab-pkrb) [package insert]. Yeonsu-gu, Incheon 22014, Republic of Korea: Celltrion, LLC. December 2018. Available at [Full Text].

30. Trazimera (trastuzumab-qyyp) [package insert]. New York, NY: Pfizer Labs. March 2019. Available at [Full Text].

31. Ontruzant (trastuzumab-dttb) [package insert]. Yeonsu-gu, Incheon, 21987, Republic of Korea: Samsung Bioepis Co. January 2019. Available at [Full Text].

32. Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) [package insert]. South San Francisco, CA: Genentech, Inc. June 2020. Available at [Full Text].

Maurie Markman, MD, MS President, Medicine and Science, Cancer Treatment Centers of America

Maurie Markman, MD, MS is a member of the following medical societies: Academy of Medicine of Cleveland & Northern Ohio, American Association for Cancer Research, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, Clinical Immunology Society, Gynecologic Oncology Group, Harris County Medical Society, International Gynecologic Cancer Society, International Society for Regional Cancer Therapy, New York State Society for Internal Medicine, Ohio State Medical Association, Public Responsibility in Medicine and Research, Society for Immunotherapy of Cancer, Society for Integrative Oncology, Society of Gynecologic Oncology, SWOG, Texas Medical Association

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Genentech; Astra-Zeneca ; Clovis; Tesaro;<br/>Received income in an amount equal to or greater than $250 from: Astra-Zeneca; Clovis; Genentech; Tesaro; Celgene; Merck; Nanology; GSK<br/>Received consulting fee from Genentech; Received consulting fee from Cellgene; Received consulting fee from Merck; Received consulting fee from Nanology.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Eric T Rush, MD, FAAP, FACMG Associate Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Clinical Geneticist, Children's Mercy Hospital of Kansas City

Eric T Rush, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, American College of Physicians, American Society for Bone and Mineral Research

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Alexion Pharmaceuticals, Ultragenyx Pharmaceutical, Biomarin Pharmaceuticals, ObsEva, Ascendis Pharma<br/>Serve(d) as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals, Ultragenyx Pharmaceutical, and Biomarin Pharmaceuticals<br/>Received research grant from: Alexion Pharmaceuticals.

Karl S Roth, MD Retired Professor and Chair, Department of Pediatrics, Creighton University School of Medicine

Karl S Roth, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Nutrition, American Pediatric Society, American Society for Nutrition, American Society of Nephrology, Association of American Medical Colleges, Medical Society of Virginia, New York Academy of Sciences, Sigma Xi, The Scientific Research Honor Society, Society for Pediatric Research, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.